In vitro activation and differentiation of naïve CD4 + and CD8 + T cells into HCV Core- and NS3-specific armed effector cells: A new role for CD4 + T cells
Viral clearance in hepatitis C virus (HCV) infection has been correlated with strong, multi-specific and sustained T cell responses. The number of functionally active effector T cells determines the outcome of infection. Only a small number of antigen-specific naïve T cells are originally present. U...
Gespeichert in:
Veröffentlicht in: | Cellular immunology 2009, Vol.259 (2), p.141-149 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Viral clearance in hepatitis C virus (HCV) infection has been correlated with strong, multi-specific and sustained T cell responses. The number of functionally active effector T cells determines the outcome of infection. Only a small number of antigen-specific naïve T cells are originally present. Upon infection, they undergo activation, clonal expansion and differentiation to become effector cells. In this study, we determined the ability of dendritic cells (DCs) to prime T cells
in vitro to become effector cells upon stimulation with various TLR ligands or IFNα. T cell priming and activation was determined by proliferation and production of effector molecules, IFN-γ and Granzyme B (GrB). HCV Core-specific T cells showed significant increase in proliferation, and the number of HCV Core-specific CD4
+ and CD8
+ T cells producing IFN-γ and GrB was higher than control or NS3-specific T cells. These
in vitro-primed CD4
+ and CD8
+ T cells exhibit the phenotype of just-activated and/or armed effector lymphocytes confirming the transition of naïve T cells to effector cells. This is the first study demonstrating the activation of GrB
+CD4
+ T cells against antigen(s) derived from HCV. Our study suggests a novel role of CD4
+ T cells in immunity against HCV. |
---|---|
ISSN: | 0008-8749 1090-2163 |
DOI: | 10.1016/j.cellimm.2009.06.009 |